This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
October 25, 2012 /PRNewswire/ --
Janssen-Cilag International announced today that the European Commission (EC) has approved a 100mg/ml oral suspension of PREZISTA® (darunavir), and the use of darunavir co-administered with low dose ritonavir, for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART)-experienced paediatric patients age 3 years and above, weighing at least 15 kg body weight. It must be taken in combination with other ARTs.
To view the Multimedia News Release, please click:
The approval is based on a 48-week analysis of ARIEL, a Phase II, open-label trial to evaluate pharmacokinetics, safety, tolerability and antiviral activity of darunavir in combination with low dose ritonavir in treatment-experienced HIV-1 infected children from 3 to < 6 years of age.
"This approval is exciting news for young children with HIV, as there is a significant and often overlooked need in the availability of specifically formulated antiretroviral therapies for this patient population. An oral suspension that makes it easier for children with HIV to take their treatment as prescribed is very important for this group, who must maintain a lifetime of daily therapy to prevent the progression of HIV to AIDS," said Dr
Avy Volari, MD, Chris Hani Baragwanath Hospital,
Johannesburg, South Africa and lead author of the ARIEL Study.
Long-term durability of treatment is an important issue for young children living with HIV, which can be affected by challenges in adherence to therapy. Strict adherence to treatment regimens and dosing schedules is crucial to prevent virological failure and the development of drug resistance. Currently, one in eight children and adolescents with HIV in
Europe experience virological failure of three drug classes within five years, which can severely limit treatment options into adolescence and adulthood.
The EC also recommended approval of the darunavir 100 mg/ml oral suspension for use in patients who are unable to swallow tablets, providing an additional way to receive treatment.